ArticleEcancermedicalscience2026
Symptom palliation with QUADSHOT regimen for advanced cervical cancer patients in Tikur Anbessa Specialised Hospital: a prospective cohort study.
Article in Ecancermedicalscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cervical cancer is the fourth most frequently diagnosed cancer and the fourth leading cause of cancer death in women. Most patients present with advanced stages, and curative treatment is not possible. The purpose of this study is to assess the symptom response and treatment-related toxicities in advanced cervical cancer patients treated with the QUADSHOT (QS) regimen. Methods: This prospective cohort study enrolled patients with histologically proven advanced cervical cancer candidates for hypo fractionated palliative radiation therapy and not candidates for curative treatment. Patients were treated with a QS radiotherapy regimen (3.7 Gy per fraction twice a day, 6 hours apart on Saturday and Sunday only, every 21 days, to a total dose of 44.4 Gy). Response to treatment was assessed at baseline, at 2, 3 and 6 months after treatment completion. Results: The mean age of the 53 enrolled patients was 56 years (SD, 10.4). Most patients (43 or 81%) had stage IIIB-IVB illness. Of the 50 patients assessed at 2 months, 43 (86%) had a complete response (CR) from vaginal bleeding, 36 (72%) from vaginal discharge and 25 (50%) from pelvic pain. In the 3rd-5th months, 46 patients were assessed; CR rates were 42 (91%), 37 (80%) and 29 (63%) for vaginal bleeding, vaginal discharge and pelvic pain, respectively. In the sixth month, 19 patients were eligible for assessment, and CR rates were 18 (94%), 17 (89%) and 13 (68%), respectively. The most common acute toxicity was fatigue, followed by grade 1 diarrhea. Four patients had grade three bladder complications. Conclusion: The QS regimen has rapid symptom relief for patients with advanced cervical cancer with minimal toxicities. The QS regimen is recommended for symptom palliation in settings with restricted resources.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.